Compare, Analyse STRIDES PHARMA SCIENCE with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 STRIDES PHARMA SCIENCE   ACTAVIS
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-21
ACTAVIS
Dec-18
STRIDES PHARMA SCIENCE/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,00015,288-   
Low Rs30410,255-   
Sales per share (Unadj.) Rs369.73,750.2-  
Earnings per share (Unadj.) Rs39.6-1,208.0-  
Cash flow per share (Unadj.) Rs62.6395.2-  
Dividends per share (Unadj.) Rs2.500-  
Avg Dividend yield %0.40-  
Book value per share (Unadj.) Rs309.115,468.0-  
Shares outstanding (eoy) m89.68332.60-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x1.83.4 51.8%   
Avg P/E ratio x16.4-10.6 -155.5%  
P/CF ratio (eoy) x10.432.3 32.2%  
Price / Book Value ratio x2.10.8 255.4%  
Dividend payout %6.30-   
Avg Mkt Cap Rs m58,4654,247,956 1.4%   
No. of employees `000NA16.9 0.0%   
Total wages/salary Rs m5,5010-   
Avg. sales/employee Rs Th073,806.6-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0-23,773.1-  
INCOME DATA
Net Sales Rs m33,1591,247,331 2.7%  
Other income Rs m73423,853 3.1%   
Total revenues Rs m33,8931,271,184 2.7%   
Gross profit Rs m6,70232,686 20.5%  
Depreciation Rs m2,063533,207 0.4%   
Interest Rs m1,50171,978 2.1%   
Profit before tax Rs m3,872-548,645 -0.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139,927 0.0%   
Tax Rs m317-6,953 -4.6%   
Profit after tax Rs m3,555-401,766 -0.9%  
Gross profit margin %20.22.6 771.3%  
Effective tax rate %8.21.3 645.0%   
Net profit margin %10.7-32.2 -33.3%  
BALANCE SHEET DATA
Current assets Rs m28,172511,590 5.5%   
Current liabilities Rs m27,383452,569 6.1%   
Net working cap to sales %2.44.7 50.3%  
Current ratio x1.01.1 91.0%  
Inventory Days Days16520 843.4%  
Debtors Days Days12266 183.7%  
Net fixed assets Rs m39,996141,191 28.3%   
Share capital Rs m8970-   
"Free" reserves Rs m26,8230-   
Net worth Rs m27,7195,144,657 0.5%   
Long term debt Rs m8,8261,811,620 0.5%   
Total assets Rs m68,1688,042,270 0.8%  
Interest coverage x3.6-6.6 -54.1%   
Debt to equity ratio x0.30.4 90.4%  
Sales to assets ratio x0.50.2 313.6%   
Return on assets %7.4-4.1 -180.9%  
Return on equity %12.8-7.8 -164.2%  
Return on capital %14.7-4.8 -303.7%  
Exports to sales %51.10-   
Imports to sales %00-   
Net fx Rs m34,6920-   
CASH FLOW
From Operations Rs m4,814445,624 1.1%  
From Investments Rs m-5,208244,812 -2.1%  
From Financial Activity Rs m-158-764,825 0.0%  
Net Cashflow Rs m-564-74,017 0.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 79.01 Rs / USD

Compare STRIDES PHARMA SCIENCE With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare STRIDES PHARMA SCIENCE With: GRANULES INDIA  CIAN HEALTHCARE  ASTRAZENECA PHARMA  PROCTER & GAMBLE HEALTH  ABBOTT INDIA  

Yellow Ad

Advertisement

Free Registration Closes at 5pm Tomorrow

We are closing the free registrations to our exclusive 'One Stock Crorepati' MEGA summit at 5 pm tomorrow.

At this event, we will reveal the details of one smallcap stock that is showing all the signs of a potential crorepati stock.

Thousands of smart Indians have already claimed their seats for this MEGA summit. So, we urge you to book your free seat now because we have a limited capacity.

Claim your free seat now

Learn more



Today's Market

Sensex Ends 150 Points Lower, Nifty Falls Below 15,800; FMCG & Banking Stocks Witness Selling(Closing)

After opening deep in the red, Indian share markets recovered most of the losses as the session progressed but still ended on a negative note.

Related Views On News

The Most Oversold Stocks in India. Is it Finally Time to Get in? (Views On News)

Jan 7, 2022

With the help of relative strength index (RSI), we take a look at top stocks that are oversold at current levels.

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks (Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Best Monopoly Stocks to Own in 2022 Views On News (Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

Is it Time to Start Buying Stocks Selectively? (Profit Hunter)

Jun 16, 2022

Some sectors have corrected by 50%. Do they merit a look?

The One Smallcap Stock I'll Recommend Now (Profit Hunter)

Jun 21, 2022

This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.

When Will the Stock Market Recover? (Views On News)

Jun 15, 2022

This is how you can tell the market is going to recover.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Jun 29, 2022 03:32 PM

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 8-QTR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS